Biotech Valuation Requires Systems Thinking Beyond Traditional Metrics

The Meb Faber Show - Better Investing | #617: Dan Rasmussen & D.A. Wallach on Biotech’s Surge, China, IPOs, US Valuations & Japan | #617

This conversation reveals how conventional wisdom in investing, particularly in specialized sectors like biotech, can lead astray when not viewed through a systems-thinking lens. The core thesis is that understanding the unique dynamics and feedback loops within a sector, rather than applying generic models, is crucial for uncovering opportunities and avoiding pitfalls. The non-obvious implication is that sectors with high dispersion and unconventional value drivers, like biotech, can offer significant diversification and return potential if approached with a specialized analytical framework. Investors and analysts seeking to gain an edge in complex markets will find value in dissecting the underlying drivers of asset prices beyond surface-level metrics. This analysis offers a strategic advantage by highlighting where traditional factor models fail and what alternative metrics can unlock deeper insights, particularly for those willing to engage with the "discomfort" of unconventional approaches.

The Biotech Enigma: Unpacking Value Beyond the Balance Sheet

The world of biotech investing often appears as a black box to outsiders, a realm governed by scientific breakthroughs and the whims of big pharma acquisitions rather than traditional financial metrics. Dan Rasmussen’s extensive research, spanning over a year, sought to demystify this sector by examining where standard equity models falter. The key insight is that biotech, particularly unprofitable biotech, operates on a fundamentally different set of principles. Traditional factors like Price-to-Earnings (P/E) ratios are meaningless for companies with no earnings. Instead, Rasmussen proposes reframing "value" as a company's market capitalization relative to its spending. This seemingly counterintuitive approach, where higher spending might indicate a more expensive but potentially more promising scientific endeavor, reveals a clear relationship with returns.

"The best thing to use is spending because these companies aren't generating any revenue they're all just spending money what you want to know is their market cap relative to spend."

-- Dan Rasmussen

This redefinition of value is critical because it acknowledges the unique nature of biotech R&D. A company burning through cash is not necessarily a poor investment; it could be aggressively funding its core mission. This contrasts sharply with other sectors where high spending without revenue is a clear red flag. The implication for investors is that a deep dive into a biotech firm's burn rate and the scientific progress it signifies is more informative than a glance at its P/E.

Furthermore, the concept of "quality" in biotech also requires a specialized lens. D.A. Wallach’s insight, which Rasmussen integrated into his research, highlights the importance of specialist holders. If dedicated biotech funds, with their in-house scientific expertise, are investing heavily in a company, it signals a higher probability of quality. Conversely, a lack of specialist ownership is a strong negative signal, suggesting that the company may be a speculative bet for non-experts. This "quality" metric acts as a powerful filter, helping to avoid potential frauds or scientifically unsound ventures that often lack the backing of seasoned industry professionals.

"If no biotech specialist fund owns a name it's a really bad signal right... it's only basically marketed to non biotech people it's almost certainly a bad idea."

-- Dan Rasmussen

The research also delves into momentum, but with a twist. Traditional momentum strategies, which track past price performance, are less effective in biotech. Instead, the concept of "peer momentum" or "indirect effects" proves more potent. By marrying clinical trial data with equity databases, Rasmussen developed a method to gauge the momentum of companies working on similar scientific endeavors. If companies in a specific therapeutic area are experiencing positive developments or acquisitions, it can signal a broader trend that benefits other firms in that space. This highlights a systemic effect where progress in one area can ripple across related companies, creating opportunities that direct momentum alone would miss. This approach acknowledges that the biotech ecosystem is interconnected, with developments in one corner influencing perceptions and valuations in others.

The China Factor: A New Frontier in Biotech Sourcing

The conversation pivots to the burgeoning role of China in the global biotech landscape, a development that surprises many. The Chinese government's strategic focus on biotech over the past decade has yielded significant results. Big pharma's acquisition strategy has shifted dramatically, with a substantial portion of early-stage assets now being sourced from China, often at a lower cost compared to Western counterparts. This presents a clear downstream effect: companies that historically relied on US and European innovation now have a vast new pool of discoveries to draw from.

Moreover, the cost and speed of early-stage clinical development have become significantly more attractive in China. This has led not only Chinese companies but also US and European firms to conduct their initial human trials there. This creates a competitive dynamic where speed and cost-efficiency become paramount, potentially forcing Western companies to adapt their development timelines and strategies to remain competitive. The analogy to China's dominance in rare earth minerals is apt: a strategic entry into a marginal part of the value chain can serve as a springboard for broader dominance.

"Big pharma whose lifeblood is buying molecules that were discovered by small companies today big pharma is increasingly buying their new early stage assets out of china... it was between 30 and 40 of their acquisitions."

-- D.A. Wallach

While skepticism regarding the quality of Chinese data persists, successful replication of trial results in larger studies outside China has begun to assuage these concerns. This shift suggests that the perceived scientific rigor is improving, driven by both internal Chinese efforts and the intense due diligence by multinational pharmaceutical companies. The long-term implication is a potential rise of homegrown Chinese pharmaceutical giants, built on a foundation of progressively more sophisticated research and development capabilities. This also poses a strategic challenge for the US government, which must consider how to respond to this evolving global landscape, potentially by re-evaluating its own regulatory approaches to remain competitive.

Valuations in a New Era: Beyond Traditional Metrics

The discussion then tackles the perennial question of whether US stocks are overvalued, a topic complicated by the divergence between traditional valuation metrics like the CAPE ratio and the persistent strength of the market. Rasmussen and Wallach present two contrasting views: the high CAPE ratio suggests a potentially overvalued market, while the implied equity risk premium, calculated by Aswath Damodaran, presents a more moderate picture. This dichotomy highlights the difficulty in applying a single valuation metric across diverse market conditions.

The argument is made that the unique wave of technological innovation in the US, from cloud computing to AI, may justify some of the elevated valuations. Companies have consistently delivered, defying predictions of mean reversion. However, this perspective is countered by the observation that outside the US, traditional value investing principles have largely held true. Cheaper companies and countries have historically performed better, suggesting that the US market's exceptionalism might be an anomaly driven by specific technological advancements rather than a fundamental shift in market dynamics.

"If you're investing abroad you know follow the old rule book because it's working and you know if you're investing in the us maybe just give up and on the index because gosh darn it these companies are doing well."

-- Dan Rasmussen

This leads to a critical insight: the persistent strength of US corporate profits, even beyond technological innovation, may be driven by deeper structural factors, such as government deficits. Chris Brightman's analysis suggests that deficits can fuel corporate revenues, which are then distributed to shareholders, creating a feedback loop that supports equity valuations. This perspective challenges the notion that technology alone is the sole driver of market performance, pointing instead to macroeconomic policies and wealth allocation dynamics. The implication is that understanding these broader systemic forces is as important as analyzing individual company performance or sector-specific trends.

Japan's Anomaly and the Global Equity Landscape

Japan emerges as a peculiar case study in global markets. Despite running significant deficits, it has avoided a debt crisis, defying conventional economic theories. The ongoing corporate governance reforms in Japan, however, present a compelling opportunity. Increased payouts in dividends and buybacks, coupled with companies sitting on substantial assets, suggest a potential for significant shareholder returns. This contrasts with the US, where profit margins have expanded dramatically, potentially driven by deficits and a greater participation in equity markets.

The widening gap between US market capitalization as a percentage of the global total and the rest of the world is striking. While some attribute this to US technological prowess, others suggest it's a reflection of greater equity participation and investment by US citizens compared to other nations. The potential for this gap to close, either through increased global investment by US investors or greater participation in their own markets by international investors, remains a key question.

"The median company in the us has about one year's worth of net income in assets whereas the median japanese company is about seven years of net income over assets."

-- Dan Rasmussen

The conversation also touches on the diminishing returns of traditional stock picking, as evidenced by the performance of quantitative hedge funds (pod shops). These sophisticated entities, capable of hedging out most systematic risks, generate only modest alpha. This suggests that for most investors, focusing on broad market exposure, perhaps with a tilt towards undervalued international markets or sectors like biotech where specialized analysis can yield insights, might be a more effective strategy than chasing alpha through individual stock selection. The core message is that in a world of increasing complexity and interconnectedness, a systems-thinking approach, combined with a willingness to challenge conventional wisdom, is the most reliable path to sustained investment success.

Key Action Items:

• Reframe Biotech Valuation: Shift from traditional P/E ratios to market cap relative to spending. Understand that high cash burn can be a sign of aggressive, promising R&D.
  • Immediate Action: When evaluating biotech companies, prioritize analyzing their cash burn rate and the scientific progress it funds.
• Identify Specialist Ownership: Use the concentration of specialist biotech funds as a proxy for quality. A lack of specialist interest is a significant red flag.
  • Immediate Action: Screen biotech investments for the presence and conviction of specialist investors.
• Explore Peer Momentum: Investigate the momentum of companies in similar therapeutic areas or working on related scientific endeavors, rather than relying solely on a company's own stock performance.
  • Over the next quarter: Develop a framework for tracking scientific similarity and peer momentum in biotech.
• Consider China's Role: Acknowledge China's growing influence in biotech R&D and clinical trials, and its potential impact on global sourcing strategies for big pharma.
  • This pays off in 12-18 months: Monitor the increasing flow of early-stage assets and clinical development from China.
• Diversify Beyond US Tech: Recognize that while US tech innovation is significant, traditional value principles are still effective in international markets.
  • Immediate Action: Review portfolio allocation to ensure adequate diversification beyond the US market, particularly in undervalued regions.
• Analyze Corporate Profit Drivers: Understand that US corporate profit expansion may be influenced by factors beyond technological innovation, such as government deficits.
  • Over the next quarter: Investigate the impact of macroeconomic policies on corporate profitability and valuations.
• Evaluate Japan's Governance Reforms: Pay attention to the corporate governance reforms in Japan, which are driving increased payouts and potentially unlocking shareholder value.
  • This pays off in 18-24 months: Consider opportunities in Japanese companies that are actively returning capital to shareholders.